Bevacizumab and Aflibercept Activate Platelets via FcγRIIa-Reference-Cited by-同舟云学术

Bevacizumab and Aflibercept Activate Platelets via FcγRIIa

Published:2015-12-22 Issue:13 Volume:56 Page:8075
ISSN:1552-5783
Container-title:Investigative Opthalmology & Visual Science
language:en
Short-container-title:Invest. Ophthalmol. Vis. Sci.

Author:

Nomura Yoko¹,Kaneko Makoto²,Miyata Kanjiro³,Yatomi Yutaka²,Yanagi Yasuo⁴

Affiliation:

1. Department of Ophthalmology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan

2. Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

3. Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

4. Department of Ophthalmology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan 4Singapore Eye Research Institute, Singapore 5Singapore National Eye Centre, Singapore

Publisher

Association for Research in Vision and Ophthalmology (ARVO)

Subject

General Medicine

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bevacizumab-induced immune thrombocytopenia in an ovarian cancer patient with mixed connective tissue disease: case report and literature review;Frontiers in Immunology;2024-06-05

2. Antibody blockade of Jagged1 attenuates choroidal neovascularization;Nature Communications;2023-05-30

3. Essential Role of Multi-Omics Approaches in the Study of Retinal Vascular Diseases;Cells;2022-12-26

4. Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life;Communications Biology;2022-08-18

5. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein;Expert Opinion on Drug Safety;2021-10-28